World's Best Scientists 2026 revealed!
Thomas E. Hutson

Thomas E. Hutson

D-Index & Metrics

Medicine

D-Index
81
Citations
60511
World Ranking
16357
National Ranking
8227

Thomas E. Hutson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Thomas E. Hutson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 335 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Thomas E. Hutson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Thomas E. Hutson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 81 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Thomas E. Hutson is affiliated with Texas Oncology in the United States. Their research focuses primarily on the treatment of renal cell carcinoma and related cancers, with significant work in cancer immunotherapy, biomarkers, oncology, and molecular biology.

They have contributed to various fields of study, including:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader disciplines, their subfields of study include:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Economics and Econometrics
  • Molecular Biology

Thomas E. Hutson's main research topics cover:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Renal and related cancers
  • Economic and Financial Impacts of Cancer
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research

The scientist frequently publishes in several academic journals, with the most common venues being:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Clinical Genitourinary Cancer
  • European Urology

Frequent co-authors working alongside Thomas E. Hutson include:

  • Camillo Porta
  • Robert J. Motzer
  • Toni K. Choueiri
  • Viktor Grünwald
  • Sumanta K. Pal

Representative recent publications authored or co-authored by Thomas E. Hutson include:

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, 2021, New England Journal of Medicine
  • Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology
  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, 2023, Journal of Clinical Oncology
  • Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study, 2023, The Lancet Oncology
  • Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial, 2022, Journal for ImmunoTherapy of Cancer

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

    Robert Motzer;Boris Alekseev;Sun Young Rha;Camillo Porta

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

    Fei Su;Amaya Viros;Carla Milagre;Kerstin Trunzer

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

    Robert J Motzer;Thomas E Hutson;Hilary Glen;M Dror Michaelson

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Matthew D. Galsky;Noah M. Hahn;Jonathan Rosenberg;Guru Sonpavde

  • Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

    Bernard Escudier;Cezary Szczylik;Thomas E. Hutson;Tomasz Demkow

  • Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

    Robert J. Motzer;Dmitry Nosov;Timothy Eisen;Igor Bondarenko

Frequent Co-Authors

Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Toni K. Choueiri
Toni K. Choueiri Harvard University
Cora N. Sternberg
Cora N. Sternberg Cornell University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Thomas Powles
Thomas Powles Queen Mary University of London
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Robert A. Figlin
Robert A. Figlin Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary education options can be a smart move for students interested in healthcare careers beyond a traditional MD. Many professionals choose to pursue further education in areas like hospital management, advanced nursing, pharmacy, or health information systems.

If you're interested in leadership roles in healthcare settings, consider the cheapest master's in healthcare administration programs available online. This pathway helps prepare you for managerial positions across the healthcare industry.

Nurses aiming for advanced clinical or executive positions may benefit from enrolling in one of the least expensive dnp programs. These flexible, online Doctor of Nursing Practice programs can open doors to higher-paying roles and increased responsibility.

For those interested in medication management or research, an accredited pharmacy degree online offers another respected career pathway.

Alternatively, technology-driven students can help transform patient care by pursuing an online bachelor's in health information management, equipping graduates with the skills to organize and secure medical data in healthcare settings.

Best Scientists Citing Thomas E. Hutson

Trending Scientists

Recently Published Articles